Education and Training
A Safety Study of SGN-CD19A for B-Cell Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: SGN-CD19A
Eligibility
Inclusion Criteria:
- Pathologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma Grade
3, diffuse large B-cell lymphoma (DLBCL), including transformed follicular histology,
Burkitt lymphoma, or B-lineage lymphoblastic lymphoma
- Relapsed, refractory, or progressive disease following at least 1 prior systemic
therapy. Patients with DLBCL or follicular lymphoma Grade 3 must have also received
intensive salvage therapy.
- Eastern Cooperative Oncology Group status of 0 or 1
- Measurable disease
Exclusion Criteria:
- Allogeneic stem cell transplant (SCT)
Ages Eligible for Study
12 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting